Background {#Sec1}
==========

Hypertension is associated with a significantly increased risk for adverse cardiac and cerebrovascular events, as well as chronic kidney disease \[[@CR1]\]. Despite optimal medical treatment, blood pressure control often remains poor and the risk for cardiovascular disease remains high. With prevalence ranging between 15 and 30%, treatment-resistant hypertension remains an important medical challenge and leads to intrinsic changes in the heart muscle and is associated with left ventricular (LV) hypertrophy and diastolic dysfunction \[[@CR2], [@CR3]\].

Catheter-based renal denervation (RDN) has been introduced as a treatment modality to optimise blood pressure control in patients with treatment-resistant hypertension by reducing sympathetic nerve activity. Unfortunately, the exact blood pressure-lowering effect of renal sympathetic denervation remains disputed, demonstrated by non-responder rates varying between 8 and 37%, depending on study-specific cohorts and definitions used \[[@CR4]\]. However, sympathetic hyperactivity has been directly associated with LV remodelling and heart rate, which makes it imperative to look at the effects of renal sympathetic denervation beyond blood pressure \[[@CR5]\]. Speckle tracking echocardiography (STE) is a new echocardiography modality that is able to measure LV characteristics, including rotation, strain and strain rate. Strain measures myocardial fibre contraction and relaxation \[[@CR6]\]. This study aims to assess the effect of RDN on functional myocardial parameters, including STE, and to identify potential differences between responders and non-responders.

Methods {#Sec2}
=======

Study population {#Sec8}
----------------

The study population consisted of 31 consecutive patients undergoing RDN in the context of treatment for resistant hypertension according to recent recommendations \[[@CR7]\]. Patients were included between December 2012 and June 2014. All patients underwent non-invasive pre-procedural renal artery imaging and were discussed in a multi-disciplinary team including interventional cardiologists, radiologists and hypertension specialists. As part of routine practice, all patients referred for RDN underwent extensive blood and urine analyses, 24-h ambulatory blood pressure measurement (24 h ABPM), echocardiography, echocardiogram (ECG) and magnetic resonance imaging (MRI) to assess renal artery eligibility and exclude renal artery stenosis in order to be able to exclude secondary causes of hypertension. Informed consent was obtained from all patients.

Definitions and end-points {#Sec9}
--------------------------

Office blood pressure measurements were recorded three times in a resting situation with intervals of 5 min using an Omron automated blood pressure monitor. Patients were classified as responders in case the drop in 6 months office systolic blood pressure was 10 mmHg or higher. In order to identify subtle changes in LV function, STE was used to obtain apical rotation, basal rotation, LV twist, twist velocity, peak untwisting velocity, time to peak untwisting velocity, global longitudinal strain (GLS), global circumferential strain (GCS), peak early and late longitudinal diastolic strain rate, and peak early and late circumferential diastolic strain rate. LV twist is defined as the maximal value of the apical systolic rotation--basal systolic rotation \[[@CR8]\].

Transthoracic echocardiography {#Sec10}
------------------------------

Echocardiography measurements were performed before the RDN procedure (baseline) and 6 months after the RDN procedure. Two-dimensional grey-scale images were obtained in the left lateral decubitus position using a commercially available ultrasound system (iE33, Philips, Best, The Netherlands), equipped with a broadband (1--5 MHz) S5-1 transducer (frequency transmitted 1.7 MHz, received 3.4 MHz). Data were analysed by two experienced echocardiographers according to the recent recommendations \[[@CR9]\]. The following echocardiographic parameters were acquired: LV end-diastolic septal (LVSd) and posterior wall thickness (LVPWd), and LV end-diastolic (LVEDD) and end-systolic dimension (LVESD). LV mass was calculated with the Devereux formula \[[@CR10]\]. Body surface area (BSA) was calculated according to the Mosteller formula \[[@CR11]\]. LV mass was indexed by BSA as recommended in the guidelines \[[@CR12]\].

From the mitral inflow pattern, peak early (E-wave velocity) and late (A-wave velocity) filling velocities, E/A ratio and E-wave velocity deceleration time were measured. Tissue Doppler was applied end-expiratory in the pulsed-wave Doppler mode at the level of the inferoseptal side of the mitral annulus from an apical four-chamber view, to obtain Em septal (peak early diastolic wave velocity of the mitral annulus) and E/Em ratio.

To acquire the highest wall tissue velocities, the angle between the Doppler beam and the longitudinal motion of the investigated structure was adjusted to a minimal level. The spectral pulsed-wave Doppler velocity range was adjusted to obtain appropriate scale.

To optimise STE, the settings were adjusted to obtain a frame rate of 50--70 frames/s. The echo images were transformed to a QLAB Advanced Quantification Software workstation (version 10.0, Philips, Best, The Netherlands) for offline analysis.

Speckle tracking analysis {#Sec11}
-------------------------

STE is an approved echocardiographic modality that provides information on regional and global ventricular function \[[@CR13]\]. In order to obtain this information, apical long-axis views (four-, three- and two-chamber views) and parasternal short-axis views (at the apical, mid-ventricular and basal LV levels) were assessed. The aortic valve closure was assessed in a parasternal long-axis view and added manually. After selecting the appropriate view, the endocardial border was automatically recognised and the tracking points were positioned. When this auto-trace function was not optimal, the tracking points were re-positioned manually on an end-diastolic frame. Next, the software automatically tracked these points using speckle tracking. LV ejection fraction was assessed using this automated endocardial border detection. Most components of LV systolic function \[rotation (clockwise rotation as viewed from the apical level has a positive value and counterclockwise rotation from the basal level has a negative value), twist, global circumferential strain (GCS) and GCS rate (GCSR)\] and diastolic function (peak untwisting velocity, time to peak untwisting velocity, peak early and late circumferential diastolic strain rate) were abstracted from parasternal short-axis views, whereas others were derived from the apical views \[systolic function: global longitudinal strain (GLS) and GLS rate (GLSR); diastolic function: peak early and late longitudinal diastolic strain rate\]. Data were exported to a spreadsheet program (Excel, Microsoft Corporation, Redmond, WA) to determine these parameters. In a previous study, we have demonstrated the reproducibility and variability of the parameters investigated in the current study in our centre \[[@CR14]\].

RDN procedure {#Sec12}
-------------

Procedures were performed using four different systems: Paradise™ (ReCor Medical, Palo Alto, CA) (*n* = 13), OneShot™ (Covidien, Campbell, CA) (*n* = 3), Vessix V2™ (Boston Scientific, Natick, MA) (*n* = 5) and Symplicity™ (Medtronic, Minneapolis, MN) (*n* = 10). Procedures were performed according to the device-specific instructions for use \[[@CR7], [@CR15]\]. All procedures were performed under conscious sedation with midazolam and fentanyl.

Statistical analysis {#Sec3}
--------------------

All continuous variables are expressed as mean ± standard deviation (SD). Continuous variables were compared using Student's *t* test. Simple linear regression of peak untwisting velocity against heart rate was performed. Categorical variables were compared with the Chi square test or Fisher's exact test when appropriate. A *p*-value \<0.05 was considered statistically significant. The statistical analysis was performed with SPSS software (version 21.0).

Results {#Sec4}
=======

Study population {#Sec13}
----------------

Thirty-one patients with resistant hypertension following RDN were enrolled in this study, all of whom completed the 6 months follow-up period. The mean age was 64 ± 10 years and 15 patients (48%) were male. A total of 19 patients were classified as responders versus 12 non-responders. Besides a significantly lower age of the responders (61 ± 10 vs. 69 ± 9 years in the non-responders; *p* = 0.028), no significant differences in patient characteristics were seen between both groups (Table [1](#Tab1){ref-type="table"}).Table 1Clinical characteristics of the study population, responder vs. non-responder at baselineAll patientsResponderNon-responder*p*-ValueBaseline (*n* = 31)Baseline (*n* = 19)Baseline (*n* = 12)Responder vs. non-responderAge (years)64 ± 1061 ± 1069 ± 90.028Male gender, *n* (%)15 (48)10 (53)5 (42)0.552BMI (kg/m^2^)29 ± 429 ± 528 ± 30.639Mean office SBP (mmHg)182 ± 18186 ± 20176 ± 150.133Mean office DBP (mmHg)94 ± 1697 ± 1489 ± 180.149Mean systolic ABPM (mmHg)150 ± 12148 ± 12152 ± 130.358Mean diastolic ABPM (mmHg)83 ± 1383 ± 1182 ± 170.946Heart rate (beats/min)68 ± 1269 ± 1265 ± 120.282CAD (%)16 (52)12 (63)4 (33)0.106Atrial fibrillation (%)2 (7)2 (11)--0.368Cardiovascular risk factors, *n* (%) Hypercholesterolaemia22 (71)15 (79)7 (58)0.204 Current smoker11 (36)6 (32)5 (42)0.619 Diabetes mellitus8 (26)7 (37)1 (8)0.086 Number of hypertensive drugs4 ± 14 ± 14 ± 10.634Patients receiving (drug class) (%) ACE inhibitors/ARBs27 (87)17 (90)10 (83)0.507 Direct renin inhibitors1 (3)--1 (8)0.387 Beta-blockers25 (81)16 (84)9 (75)0.435 Alpha-blockers9 (29)4 (21)5 (42)0.168 Calcium channel blockers25 (81)16 (84)9 (75)0.435 Aldosterone antagonist4 (13)3 (16)1 (8)0.493 Diuretics22 (71)13 (68)9 (75)0.417 Central acting agent3 (10)1 (5)2 (17)0.328Values are mean ± standard deviation (SD) or *n* (%)*BMI* Body mass index; *SBP* systolic blood pressure; *DBP* diastolic blood pressure; *ABPM* ambulatory blood pressure monitoring; *CAD* coronary artery disease; *ACE* angiotensin-converting enzyme; *ARBs* angiotensin receptor blocker

Blood pressure {#Sec14}
--------------

A significant decrease was seen in office-based systolic blood pressure (SBP) and diastolic blood pressure (DBP) after RDN at 6 months follow-up: 182 ± 18 vs. 163 ± 27 mmHg (*p* \< 0.001) and 94 ± 16 vs. 85 ± 14 mmHg (*p* = 0.001), respectively. The same applied for the systolic 24 h ABPM after RDN (150 ± 12  vs. 142 ± 18 mmHg; *p* = 0.017) and the diastolic 24 h ABPM after RDN (83 ± 13 vs. 78 ± 11 mmHg; *p* = 0.006) (Table [2](#Tab2){ref-type="table"}).Table 2Clinical, echocardiographic and speckle tracking parameters in patients following renal denervationBaselineFollow-up (6 months)*p*-ValueClinical parameters Mean office SBP (mmHg)182 ± 18163 ± 27\<0.001 Mean office DBP (mmHg)94 ± 1685 ± 140.001 Mean systolic ABPM (mmHg)150 ± 12142 ± 180.017 Mean diastolic ABPM (mmHg)83 ± 1378 ± 110.006 Heart rate (beats/min)68 ± 1263 ± 110.016Echocardiographic parameters LA size (mm)45.1 ± 7.944.5 ± 6.80.523 LAVI (mL/m^2^)36.8 ± 10.935.6 ± 11.00.335 IVSd (mm)10.8 ± 2.110.3 ± 1.80.105 LVPWd (mm)8.8 ± 1.48.3 ± 1.50.020 LVEDD (mm)53.8 ± 8.155.5 ± 7.90.028 LVESD (mm)37.7 ± 8.739.5 ± 8.30.048 LVEF (%)59.5 ± 11.058.1 ± 10.10.123 LVMI (g/m^2^)105.8 ± 33.8102.6 ± 30.20.133Doppler indices E (cm/s)67.2 ± 20.565.0 ± 23.10.519 A (cm/s)69.7 ± 14.264.4 ± 14.00.044 E/A ratio1.0 ± 0.31.0 ± 0.40.557 DET (ms)219.7 ± 51.6219.7 ± 84.30.996 Em septal (cm/s)5.5 ± 1.85.1 ± 1.70.134 E/Em ratio12.3 ± 4.712.5 ± 3.00.840Speckle tracking echocardiography GLS (%)−19.6 ± 4.2−19.9 ± 3.50.653 GCS (%)−27.3 ± 6.5−27.2 ± 5.30.877 Early GLSR0.89 ± 0.250.89 ± 0.210.932 Late GLSR0.80 ± 0.230.82 ± 0.240.495 Early GCSR1.88 ± 0.621.80 ± 0.510.470 Late GCSR1.39 ± 0.501.32 ± 0.440.432 Apical GR (°)4.8 ± 3.44.3 ± 2.70.542 Basal GR (°)−4.2 ± 2.0−3.5 ± 2.20.212 Twist (°)8.7 ± 4.47.4 ± 3.70.178 Twist velocity (°/s)15.5 ± 12.913.7 ± 12.10.665 Peak untwisting velocity (°/s)−70.6 ± 28.5−56.1 ± 24.90.025 Time to peak untwisting velocity (s)0.08 ± 0.070.09 ± 0.080.707 LVEDV (mL)76.1 ± 28.482.6 ± 34.20.152 LVESV (mL)30.5 ± 17.933.9 ± 22.90.146 LVEF (%)61.8 ± 10.161.5 ± 8.50.803Values are mean ± SD*SBP* Systolic blood pressure; *DBP* diastolic blood pressure; *ABPM* ambulatory blood pressure monitoring; *LA* left atrial; *LAVI* left atrial volume indexed; *IVSd* interventricular septum thickness (diastole); *LVPWd* left ventricular posterior wall thickness (diastole); *LVEDD* left ventricular end-diastolic dimension; *LVESD* left ventricular end-systolic dimension; *LVEF* left ventricular ejection fraction; *LVMI* left ventricular mass index; *E* peak early phase filling velocity; *A* peak atrial phase filling velocity; *DET* deceleration time; *Em* peak early wave velocity; *GLS* global longitudinal strain; *GCS* global circumferential strain; *GLSR* global longitudinal strain rate (early and late diastole); *GCSR* global circumferential strain rate (early and late diastole); *GR* global rotation (apical and basal level). Twist is defined as the instantaneous left ventricular peak systolic twist. The peak untwisting velocity is the peak diastolic de-rotation velocity. *EDV* End-diastolic volume; *ESV* end-systolic volume

Conventional echocardiography and STE {#Sec15}
-------------------------------------

In the total cohort, significant differences at baseline versus the 6-month follow-up period were noted in LVPWd, A-wave velocity and peak untwisting velocity. LVPWd decreased significantly from 8.8 ± 1.4 mm at baseline to 8.3 ± 1.5 mm at follow-up (*p* = 0.020). LV mass index (MI) reduced by 3.2 ± 11.6 g/m^2^ at 6 months. A-wave velocity decreased significantly from 69.7 ± 14.2 cm/s at baseline to 64.4 ± 14.0 cm/s at follow-up (*p* = 0.044). No significant changes were seen in the other conventional echocardiographic parameters. Furthermore, peak untwisting velocity decreased significantly from −70 ± 28.5°/cm at baseline to −56 ± 24.9°/cm at follow-up (*p* = 0.025) (Table [2](#Tab2){ref-type="table"}).

Stratifying the cohort in responders and non-responders did reveal significant changes from baseline to follow-up in A-wave velocity and peak untwisting velocity in the responders (Fig. [1](#Fig1){ref-type="fig"}). In the non-responders, LVESD increased significantly from 37.4 ± 9.3 to 39.7 ± 10.1 mm (*p* = 0.013), although it should be noted that LV ejection fraction (EF) showed no difference. Also, no differences were found in the more sensitive systolic parameters GLS, GCS and LV twist.Fig. 1Change in A-wave velocity and peak untwisting velocity at baseline and 6 months follow-up, categorised by responders and non-responders

Comparing the baseline characteristics of both cohorts, no difference was observed in the LVMI at baseline in the responders as compared to the non-responders (98 ± 25.4 vs. 116 ± 42.9 g/m^2^) (Table [3](#Tab3){ref-type="table"}).Table 3Baseline and 6-month follow-up parameters in patients following renal denervation, responders vs. non-respondersResponder (*n* = 19)Non-responder (*n* = 12)*p* valueBaseline6 months*p* valueBaseline6 months*p* valueResponder vs. non-responder at baselineEchocardiographic parameters LA size (mm)44.6 ± 8.044.2 ± 7.50.71245.8 ± 7.944.9 ± 5.70.5850.706 LAVI (mL/m^2)^37.3 ± 11.136.0 ± 12.20.39436.1 ± 11.334.9 ± 9.70.6370.855 IVSd (mm)10.5 ± 2.010.3 ± 2.20.40811.3 ± 2.210.3 ± 1.20.1760.352 LVPWd (mm)8.7 ± 1.68.3 ± 1.80.1309.0 ± 1.28.4 ± 1.20.0890.546 LVEDD (mm)52.9 ± 7.855.1 ± 6.80.06055.1 ± 8.756.2 ± 9.70.2890.484 LVESD (mm)37.9 ± 8.539.4 ± 7.30.28437.4 ± 9.339.7 ± 10.10.0130.872 LVEF (%)57.6 ± 10.157.0 ± 9.50.58762.5 ± 12.259.8 ± 11.10.0880.235 LVMI (g/m^2^)98.8 ± 25.498.8 ± 25.4^a^116 ± 42.9108.5 ± 36.90.1360.151Doppler indices E (cm/s)72.2 ± 19.570.9 ± 24.70.75959.7 ± 20.556.2 ± 17.70.5550.103 A (cm/s)69.9 ± 17.061.4 ± 14.40.02769.3 ± 10.068.4 ± 13.00.7850.914 E/A ratio1.0 ± 0.31.1 ± 0.30.3740.9 ± 0.30.9 ± 0.40.8890.249 DET (ms)207.5 ± 40.6189.7 ± 41.70.155238.1 ± 62.2264.6 ± 111.30.4000.113 Em septal (cm/s)5.6 ± 1.65.3 ± 1.70.5155.5 ± 2.14.8 ± 1.80.1510.882 E/Em ratio12.5 ± 3.612.5 ± 3.30.87212.2 ± 5.812.3 ± 2.90.8980.875Speckle tracking echocardiography Twist (°)8.0 ± 3.86.8 ± 3.80.24210.1 ± 5.28.6 ± 3.50.4920.278 Twist velocity (°/s)14.7 ± 13.213.3 ± 11.20.79217.1 ± 13.214.5 ± 14.50.7400.673 Peak untwisting velocity (°/s)−73.8 ± 30.4−49.7 ± 23.80.006−64.6 ± 25.5−68.2 ± 23.50.6370.475 Time to peak untwisting velocity (s)0.07 ± 0.080.09 ± 0.080.4310.10 ± 0.060.08 ± 0.070.5090.389 GLS (%)−19.2 ± 4.7−19.5 ± 3.90.661−20.6 ± 3.0−20.6 ± 2.40.9380.480 GCS (%)−27.2 ± 6.7−26.5 ± 5.90.476−27.5 ± 6.5−28.5 ± 4.20.6570.916 Early GLSR0.90 ± 0.280.89 ± 0.190.8090.87 ± 0.210.91 ± 0.260.4600.625 Late GLSR0.76 ± 0.250.77 ± 0.240.8400.86 ± 0.190.92 ± 0.220.4290.188 Early GCSR1.91 ± 0.561.81 ± 0.500.3391.81 ± 0.751.77 ± 0.570.8830.736 Late GCSR1.26 ± 0.531.15 ± 0.330.3201.62 ± 0.341.62 ± 0.480.9900.094Values are mean ± SD*LA* Left atrial; *LAVI* left atrial volume index; *IVSd* interventricular septum thickness (diastole); *LVPWd* left ventricular posterior wall thickness (diastole); *LVEDD* left ventricular end-diastolic dimension; *LVESD* left ventricular end-systolic dimension; *LVEF* left ventricular ejection fraction; *LVMI* left ventricular mass index; *E* peak early phase filling velocity; *A* peak atrial phase filling velocity; *DET* deceleration time; *Em* peak early wave velocity. Twist is defined as the instantaneous left ventricular peak systolic twist. The peak untwisting velocity is the peak diastolic de-rotation velocity. *GLS* Global longitudinal strain; *GCS* global circumferential strain; *GLSR* global longitudinal strain rate (early and late diastole); *GCSR* global circumferential strain rate (early and late diastole)^a^Standard error of the difference

Predictors for response {#Sec16}
-----------------------

No association was found between the clinical characteristics, conventional echocardiographic and speckle tracking parameters which could predict response.

Discussion {#Sec5}
==========

The aim of this study was to assess if RDN resulted in functional and structural cardiac changes as assessed using both conventional 2D echocardiography and 2D STE. A secondary objective was to assess any differences in these parameters between responders and non-responders. We observed a significant difference in blood pressure and heart rate at 6 months post procedure. Echocardiographically, at 6 months, a significant difference was noted in LVPWd and A-wave velocity. Additionally, STE demonstrated a significant difference in peak untwisting velocity.

Persistent sympathetic nervous system hyperactivity plays a critical role in hypertension and is associated with significant structural and functional cardiac changes \[[@CR16]\]. In this study, we found that RDN significantly reduced office blood pressure by 18.9 ± 26.8/8.5 ± 13.5 mmHg (*p* \< 0.001) and heart rate by 4.5 ± 9.9 beats/min (*p* = 0.016). In line with these findings, we observed a significant decrease in LVPWd (0.47 ± 1.0 mm), along with a reduction in LVMI of 3.2 ± 11.6 g/m^2^ in the total cohort. The fact that this reduction did not reach statistical significance could be due to a lack of power.

Looking further into diastolic function, which is strongly related to hypertension and blood pressure control, revealed a pseudonormal diastolic dysfunction, based on normal E/A ratio, but increased left atrial (LA) dimension and E/Em ratio in the overall study population. We observed a significant decrease in the A-wave velocity by 5.3 ± 13.2 cm/s (*p* = 0.044) in the total population. In the responders, the difference in the A-wave velocity even decreased to 8.5 ± 13.8 cm/s (*p* = 0.027). The decrease in A-wave velocity after renal denervation could implicate an improvement in the LV relaxation and a subsequent better diastolic function \[[@CR17]\]. Additionally, a pseudonormal diastolic function may reflect a decrease in LV compliance and a moderate increase in LA pressure in our population, with impaired relaxation and prolonged A-wave velocity before treatment. The link between peak untwisting velocity and A-wave velocity may be explained by the rate of uncoiling. In other words, it is likely that less force is needed for the active atrial contraction during late diastolic filling after blood pressure lowering. The relation between LV untwisting and the conventional parameters was also described in previous work, in which a positive correlation between untwisting rate and A-wave velocity was found, while there was no correlation between E-wave velocity and untwisting rate \[[@CR8]\]. However, these findings should be interpreted with caution, as no differences were noted in other echocardiographic parameters determining diastolic function, such as the E/Em ratio and LA dimensions.

Hypertensive patients have a greater risk of developing cardiac fibrosis, myocyte hypertrophy and diastolic dysfunction \[[@CR18]\]. These changes may influence the LV twist and rotation \[[@CR19]\]. LV twist is a wringing motion of the heart as the apex rotates with respect to the base around the LV long axis, which is a key element for regulating LV systolic and diastolic mechanics \[[@CR20]\]. LV twist is derived from the dynamic interaction between subendocardial and subepicardial myocardial fibres, the latter defining the direction of the LV twist. It is known that, in myocardial fibrosis and LV hypertrophy, which is related to pressure overload, impairment appears frequently in the subendocardial layer, leading to a dominance of the subepicardial fibres \[[@CR21]\]. This might explain the increased LV twist in patients with LV hypertrophy. LV untwisting starts after the peak LV twist. In a healthy population, the peak systolic twist is supposed to store potential energy and is thought to contribute towards diastolic suction and facilitate early LV diastolic filling. Previous work from our group demonstrated that peak untwisting velocity is increased in hypertrophic cardiomyopathy patients with mild diastolic dysfunction, as well as in aortic stenosis patients \[[@CR8], [@CR22]\]. Our study is the first to demonstrate a significant decrease in peak untwisting velocity of 14.5 ± 28.9°/s (*p* = 0.025) in patients undergoing RDN. This change was mainly driven by a change in peak untwisting velocity by 24.1 ± 28.7°/s (*p* = 0.006) in the responders. In non-responders, no difference following RDN was observed. The decrease in untwisting velocity after renal denervation could implicate an improvement in the LV relaxation and a subsequent better diastolic function, similar to A-wave velocity. One may hypothesise that, in hypertension patients, like in hypertrophic cardiomyopathy and aortic stenosis patients, increased peak untwisting velocity serves as a compensatory mechanism for abnormal relaxation and prevents the need to increase LA pressure \[[@CR22], [@CR23]\]. RDN probably leads to an improvement of these specific changes in LV rotational and de-rotational mechanics, especially in responders. However, no significant change was seen in twist and twist velocity. Finally, we observed a significant decrease in heart rate following RDN in our population. This is in line with several randomised controlled studies which also demonstrated a decrease in heart rate following RDN \[[@CR24], [@CR25]\]. Interestingly, a similar decrease in heart rate was observed in the (sham) control arm of both studies, suggesting that RDN by itself has no significant effect on heart rate. Additional exploratory analyses in our study ruled out a correlation between heart rate and untwisting velocity (*R* ^2^ = 0.1%).

Future studies, comparing hypertensive patients with a healthy control group, may be warranted in order to investigate myocardial geometry changes in hypertensive subjects in the context of diastolic LV twisting and untwisting, blood pressure or heart rate independently.

Limitations {#Sec6}
===========

Data are derived from a small patient population and a lack of power might have impacted our findings. Furthermore, accurate assessment of changes in cardiac systolic and diastolic function and volumes with conventional echocardiography produces limited image quality in patients with a body mass index (BMI) above 25 kg/m^2^. In some patients (*n* = 6), automatically detected LV contours had be corrected manually, which might have impacted the reliability of the measurements. Four different renal denervation systems were used. Based on individual previous studies, the blood pressure-lowering effect of these individual devices remains in the same range; however, a differential effect on the echocardiographic parameters measured in our study could not be excluded.

Conclusion {#Sec7}
==========

Renal sympathetic denervation (RDN) reduced blood pressure and heart rate, and significantly improved functional myocardial parameters such as A-wave velocity and peak untwisting velocity in patients with treatment-resistant hypertension, suggesting potential pleiotropic beneficial effects of renal sympathetic denervation on myocardial mechanics. Further dedicated studies are needed to elucidate the potential role of RDN on echocardiographic parameters.
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